Literature DB >> 23015017

A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells.

Alisa Knapman1, Marina Santiago, Yan Ping Du, Philip R Bennallack, Macdonald J Christie, Mark Connor.   

Abstract

Opioids are widely prescribed analgesics, but their use is limited due to development of tolerance and addiction, as well as high variability in individual response. The development of improved opioid analgesics requires high-throughput functional assays to assess large numbers of potential opioid ligands. In this study, we assessed the ability of a proprietary "no-wash" fluorescent membrane potential dye to act as a reporter of µ-opioid receptor (MOR) activation and desensitization via activation of G-protein-coupled inwardly rectifying potassium channels. AtT-20 cells stably expressing mouse MOR were assayed in 96-well plates using the Molecular Devices FLIPR membrane potential dye. Dye emission intensity decreased upon membrane hyperpolarization. Fluorescence decreased in a concentration-dependent manner upon application of a range of opioid ligands to the cells, with high-efficacy agonists producing a decrease of 35% to 40% in total fluorescence. The maximum effect of morphine faded in the continued presence of agonist, reflecting receptor desensitization. The effects of opioids were prevented by prior treatment with pertussis toxin and blocked by naloxone. We have demonstrated this assay to be an effective method for assessing ligand signaling at MOR, which may potentially be scaled up as an additional high-throughput screening technique for characterizing novel opioid ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015017     DOI: 10.1177/1087057112461376

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  22 in total

1.  Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells.

Authors:  Lia Baki; Miguel Fribourg; Jason Younkin; Jose Miguel Eltit; Jose L Moreno; Gyu Park; Zhanna Vysotskaya; Adishesh Narahari; Stuart C Sealfon; Javier Gonzalez-Maeso; Diomedes E Logothetis
Journal:  Pflugers Arch       Date:  2016-01-16       Impact factor: 3.657

2.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

3.  Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 4.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.

Authors:  William J Redmond; Erin E Cawston; Natasha L Grimsey; Jordyn Stuart; Amelia R Edington; Michelle Glass; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-11-17       Impact factor: 8.739

6.  A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

7.  Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Authors:  Thomas Günther; Michael Culler; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-03-11

8.  Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA.

Authors:  Eric Sparkes; Elizabeth A Cairns; Richard C Kevin; Felcia Lai; Katharina Elisabeth Grafinger; Shuli Chen; Marie H Deventer; Ross Ellison; Rochelle Boyd; Lewis J Martin; Iain S McGregor; Roy R Gerona; David E Hibbs; Volker Auwärter; Michelle Glass; Christophe Stove; Samuel D Banister
Journal:  RSC Med Chem       Date:  2021-10-25

9.  The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse.

Authors:  Samuel D Banister; Shane M Wilkinson; Mitchell Longworth; Jordyn Stuart; Nadine Apetz; Katrina English; Lance Brooker; Catrin Goebel; David E Hibbs; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou
Journal:  ACS Chem Neurosci       Date:  2013-04-17       Impact factor: 4.418

10.  Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.

Authors:  Erin E Cawston; William J Redmond; Courtney M Breen; Natasha L Grimsey; Mark Connor; Michelle Glass
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.